Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020

•The SFR selected the most critical questions Rheumatologists must contend in the management of their patients with rheumatic diseases during COVID-19 pandemic.•A group of 10 experts from SFR and CRI boards proposed responses based on the current knowledge of May 2020.•In most circumstances, there is no contraindication to the initiation or continuation of anti-inflammatory drugs as well as DMARDs.•If signs suggestive of infection (coronavirus or other) occur, treatments should be discontinued and resumed, if necessary, after 2 weeks without any symptoms.